Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spotlight on rizatriptan in migraine.

Keri Wellington1, Blair Jarvis

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

CNS Drugs
|September 25, 2002
PubMed
Summary

Rizatriptan effectively treats moderate to severe migraine by providing rapid pain relief and restoring function. It offers superior efficacy compared to placebo and other triptans, with generally mild side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Drugs·2007
Same author

Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.

Drugs & aging·2007
Same author

Cyberball: a program for use in research on interpersonal ostracism and acceptance.

Behavior research methods·2006
Same author

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Drugs·2006
Same author

Insulin glulisine.

Drugs·2006
Same author

Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Drugs·2006

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a common neurological disorder characterized by severe head pain and associated symptoms.
  • Serotonin 5-HT(1) receptor agonists, like rizatriptan, are a key therapeutic class for acute migraine treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of rizatriptan for acute migraine treatment.
  • To compare rizatriptan's effectiveness against placebo and other triptans (sumatriptan, zolmitriptan, naratriptan).

Main Methods:

  • Review of clinical trials assessing rizatriptan 5mg and 10mg oral formulations.
  • Comparative analysis of efficacy endpoints including pain relief, pain-free state, functional ability, and symptom resolution.
  • Assessment of adverse event profiles.

Main Results:

  • Rizatriptan demonstrated superior efficacy to placebo in pain relief, achieving a pain-free state, restoring functional ability, and improving quality of life.
  • Rizatriptan provided faster pain relief and greater nausea reduction than oral sumatriptan.
  • Rizatriptan 10mg showed higher efficacy than zolmitriptan 2.5mg and naratriptan 2.5mg in achieving a pain-free state and normal functional ability at 2 hours.

Conclusions:

  • Rizatriptan is a highly effective and generally well-tolerated option for the acute management of moderate to severe migraine.
  • Its rapid onset of action and superior efficacy compared to other triptans support its consideration as a first-line treatment.
  • Long-term efficacy and tolerability are maintained, reinforcing its role in migraine therapy.

Related Experiment Videos